CML in Elderly: Does Age Matter?

Autor: Lokesh KN; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Pehalajani JK; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Loknatha D; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Jacob LA; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Babu MCS; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Rudresha AH; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Rajeev LK; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Smitha SC; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Ashok KP; Department of Medical Oncology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India., Madhumathi DS; Department of Pathology, Kidwai Cancer Institute, Marigowda Road, Bangalore, 560029 India.
Jazyk: angličtina
Zdroj: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion [Indian J Hematol Blood Transfus] 2020 Jan; Vol. 36 (1), pp. 47-50. Date of Electronic Publication: 2019 Jun 06.
DOI: 10.1007/s12288-019-01143-4
Abstrakt: The median age of diagnosis for chronic myeloid leukemia (CML) in India is 35 years on the contrary to western literature which is 47 years. The outcome of the elderly patient in CML TKI era is not reported from the Indian population. However, Western literature suggests that use of TKI alleviate the adverse impact of age in outcomes of CML. This study was carried out to analyze the clinical profile and outcome of elderly, in comparison with younger patients with CML. We retrospectively analyzed CML patients treated at our department from January 2008 to December 2017. The data cutoff date was December 2018. The cohorts of 712 patients were divided into two groups. Patients belonging to the age group of ≥ 60 years were classified as the study group and those who were 18-60 years were used as controls. Patient's clinical history, examination and milestones in terms of achieving hematological, molecular responses and toxicity profile were also recorded. The total of 712 patients, 52 patients in the study group and 660 patients in the control group were treated during the study period. The study group was having more co-morbidities than the control group (15.3% vs. 4.5%). Patients having high-risk EUTOS score were similar in both groups (38.4% vs. 37.6%). The patients presented in blast phase were higher in the study group as compared to control group (9.6% vs. 6.36%) but the differences were not statistically significant. Rates of achieving a hematological response at 3 months (85.1% vs. 86.89%) and the major molecular response at 18 months (54.3% vs. 60.16%) were almost similar in both groups. However, hematological toxicity, muscle cramps and gastritis were reported more in elderly patients. The outcome of CML patients in TKI era do not differ in elderly patients. However, toxicity profile was not significantly inferior in elderly patients.
Competing Interests: Conflict of interestThe authors declare that they have no conflict of interest.
(© Indian Society of Hematology and Blood Transfusion 2019.)
Databáze: MEDLINE
Externí odkaz: